Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)

Phase III COVID-19 ARDS Company Continues Quest to Cure COPD Through Developing Clinically Applicable Solutions

ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International announced today data and patent filing on a new approach to treating chronic obstructive pulmonary disease (COPD).

The Company demonstrated that administration of a combination of the FDA approved drug G-CSF, together with a proprietary anti-oxidant/NF-kappa B inhibiting formulation resulted in suppression of COPD in the elastase animal model. Furthermore, the Company demonstrated synergy between the new approach and JadiCell administration.

“Our Company is committed to curing COPD. To develop a real cure, we need to create a protocol that utilizes both exogenous stem cell administration, such as JadiCells, as well as properly stimulating the patient’s endogenous regenerative mechanisms using approaches such as the one disclosed today,” said Dr. James Veltmeyer, Chief Medical Officer of the Company.

Therapeutic Solutions International currently has an ongoing Phase III clinical trial for COVID-19 induced Acute Respiratory Distress Syndrome and has been granted an IND number by the FDA for treatment of COPD.

“Our commitment to COPD is based on the fact that treatments have largely been addressing symptoms,” said Timothy Dixon, President and CEO of the Company. “As part of our zeal to develop regenerative approaches to this problem, we are developing a pipeline of products that can fit into current COPD treatment protocols. The endogenous stem cell stimulating approach is being created as a maintenance therapy that will be used with the JadiCell approach.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.

Contacts

Timothy G. Dixon

[email protected]